Agenus PE Ratio 2006-2021 | AGEN

Current and historical p/e ratio for Agenus (AGEN) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Agenus PE ratio as of October 26, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Agenus PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-27 3.81 0.00
2021-06-30 5.49 $-1.12 0.00
2021-03-31 2.72 $-1.03 0.00
2020-12-31 3.18 $-1.07 0.00
2020-09-30 4.00 $-1.09 0.00
2020-06-30 3.93 $-1.14 0.00
2020-03-31 2.45 $-1.24 0.00
2019-12-31 4.07 $-0.81 0.00
2019-09-30 2.58 $-0.99 0.00
2019-06-30 3.00 $-0.95 0.00
2019-03-31 2.97 $-0.81 0.00
2018-12-31 2.38 $-1.46 0.00
2018-09-30 2.14 $-1.41 0.00
2018-06-30 2.27 $-1.49 0.00
2018-03-31 4.71 $-1.57 0.00
2017-12-31 3.26 $-1.22 0.00
2017-09-30 4.41 $-1.17 0.00
2017-06-30 3.91 $-1.27 0.00
2017-03-31 3.77 $-1.28 0.00
2016-12-31 4.12 $-1.47 0.00
2016-09-30 7.18 $-1.35 0.00
2016-06-30 4.05 $-1.04 0.00
2016-03-31 4.16 $-1.24 0.00
2015-12-31 4.54 $-1.15 0.00
2015-09-30 4.60 $-1.38 0.00
2015-06-30 8.63 $-1.35 0.00
2015-03-31 5.13 $-0.94 0.00
2014-12-31 3.97 $-0.67 0.00
2014-09-30 3.11 $-0.42 0.00
2014-06-30 3.22 $-0.53 0.00
2014-03-31 3.17 $-0.81 0.00
2013-12-31 2.64 $-1.15 0.00
2013-09-30 2.77 $-1.22 0.00
2013-06-30 3.79 $-1.22 0.00
2013-03-31 3.89 $-1.13 0.00
2012-12-31 4.10 $-0.49 0.00
2012-09-30 4.61 $-0.55 0.00
2012-06-30 5.24 $-0.59 0.00
2012-03-31 6.60 $-0.58 0.00
2011-12-31 2.00 $-1.17 0.00
2011-09-30 2.82 $-1.06 0.00
2011-06-30 4.68 $-1.14 0.00
2011-03-31 5.46 $-1.14 0.00
2010-12-31 6.06 $-1.44 0.00
2010-09-30 5.94 $-1.14 0.00
2010-06-30 4.87 $-1.56 0.00
2010-03-31 4.36 $-2.28 0.00
2009-12-31 3.84 $-2.52 0.00
2009-09-30 12.42 $-2.22 0.00
2009-06-30 12.54 $-2.46 0.00
2009-03-31 2.94 $-2.58 0.00
2008-12-31 2.88 $-2.94 0.00
2008-09-30 9.48 $-4.32 0.00
2008-06-30 11.58 $-4.80 0.00
2008-03-31 14.16 $-4.98 0.00
2007-12-31 12.24 $-4.92 0.00
2007-09-30 14.22 $-5.52 0.00
2007-06-30 17.16 $-5.46 0.00
2007-03-31 13.38 $-6.00 0.00
2006-12-31 10.98 $-7.02 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.884B $0.088B
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86